However, for patients with complex metabolic needs, such as those at risk for non-alcoholic fatty liver disease (NAFLD) or dyslipidaemia, Retatrutide could be a valuable option - especially as future long-term studies may reveal additional benefits from glucagon receptor activation. Here, GCGR is linked to metabolic dysfunction-associated steatotic liver disease.